Application of interleukin-37b in preparation of product for preventing and treating Kawasaki disease

A technology for interleukin and Kawasaki disease, applied in medical preparations containing active ingredients, cardiovascular system diseases, peptide/protein components, etc., to reduce endothelial cell apoptosis and inflammatory response, and alleviate coronary arteritis in Kawasaki disease Effect

Pending Publication Date: 2021-10-19
THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, whether IL-37 and its isoforms can inhibit endothelial cell apoptosis, especially that induced by KD, remains unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of interleukin-37b in preparation of product for preventing and treating Kawasaki disease
  • Application of interleukin-37b in preparation of product for preventing and treating Kawasaki disease
  • Application of interleukin-37b in preparation of product for preventing and treating Kawasaki disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] 2ml blood samples were collected from each healthy control and acute KD patients, and then centrifuged to collect serum. The collected serum samples were routinely stored at -80°C within 4 hours after collection for later use. In addition, for all participants, written informed consent was given for their clinical information and blood samples for academic research. This study was commissioned by the Ethics Committee of Wenzhou Medical University and conducted in accordance with the Declaration of Helsinki.

[0069] The serum concentration of IL-37 was determined with the corresponding enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. Human IL-37 ELISA kit was purchased from SolarBio (Beijing, China).

[0070] To preliminarily confirm that IL-37 may be involved in the pathological process of KD, we first detected the level of IL-37 in the serum of KD patients and compared it with healthy controls (HC). like figure 1 As show...

Embodiment 2

[0077] CAWS were prepared from Candida albicans NBRC1385. Briefly, Candida albicans was cultured in C-limiting medium at 27°C at 170 rpm for 2 days. Next, add an equal amount of ethanol and place in a refrigerator at 4 °C overnight. The precipitate was collected by centrifugation, dissolved in water, stirred for 2 h and then centrifuged again. Finally, the soluble fraction was obtained, and after adding an equal amount of ethanol, it was placed in a refrigerator at 4° C. overnight, and then centrifuged again. The resulting precipitate was collected with acetone, and after air drying, the resulting CAWS were dissolved in PBS buffer and autoclaved before use.

[0078] The KD animal model was 3-4 weeks old male C57BL / 6 mice, which were purchased from Wenzhou Medical University, certificate number: SCXK[ZJ]2005-0019. Guidelines for the Care and Use of Animals. The breeding temperature is 23±2°C, and the humidity is 50±5%. The mice were randomly divided into 3 groups: PBS grou...

Embodiment 3

[0086] According to the method of Example 1, KD patient serum (KD) and healthy control serum (HC) were obtained.

[0087] Human umbilical vein endothelial cells (HUVECs) and human monocytic leukemia cell line (THP1) were used as research objects. HUVECs and THP1 were identified by short tandem repeat (STR) markers by Gene Detection Biotech (Suzhou, China) and KeyCen Biotechnology (Nanjing, China) and were free of mycoplasma contamination. HUVEC and THP1 were routinely cultured according to previous reports. If necessary, human umbilical vein endothelial cells were pretreated with IL-37b protein for 1 h, and then co-cultured with THP1 cells for 24 h. All cultures were grown in healthy control serum or KD patient serum. Serum was diluted in DMEM medium.

[0088] To study the protective effect of IL-37b, we added different concentrations of IL-37b (0 ng / ml, 10 ng / ml and 100 ng / ml) to human umbilical vein endothelial cells and co-cultured them with KD serum-treated THP1 cells. U...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of interleukin-37b in preparation of a product for preventing and / or treating Kawasaki disease. The product can regulate and control Kawasaki disease coronary artery injury, endothelial cell apoptosis and / or vascular inflammation. The interleukin-37b inhibits endothelial cell apoptosis and vasculitis through IL-1R8 receptor mediated ERK and NF [kappa] B inactivation, so that the Kawasaki disease coronary arteritis is relieved, and finally the purpose of preventing and treating the Kawasaki disease is achieved. Research results show that the interleukin-37b plays an effective role in protecting coronary injury of the Kawasaki disease, and new evidence is provided for using the interleukin-37b as a potential candidate drug for treating the Kawasaki disease.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals, in particular to the use of interleukin-37b in the preparation of products for treating Kawasaki disease. Background technique [0002] Kawasaki disease (KD) is a systemic immune vasculitis that mainly affects children. The most serious complication of KD is coronary artery injury, including coronary artery dilatation, coronary artery aneurysm (CAA), and stenosis. Clinically, the most advanced treatment strategy is intravenous immunoglobulin (IVIG) combined with oral aspirin. In the absence of early intervention, approximately 25% of KD patients will develop CAA. Even with prompt treatment, there remains a high risk of unacceptably high CAA. Therefore, it is urgent to explore new and potential therapeutic strategies for the clinical treatment of KD and its complications. [0003] Interleukin-37 (IL-37), a newly reported member of the IL-1 family, is a new type of anti-inflammatory cytokine t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/20A61P29/00A61P9/14A61P9/10
CPCA61K38/20A61P29/00A61P9/14A61P9/10
Inventor 贾尝诸葛颖芝张舒驰褚茂平
Owner THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap